📢 #StockUpdate | Cipla Ltd (CMP: ₹1,572) 💊 India’s pharma heavyweight delivers a steady Q1 and breaks out on the charts!

🔍 Short-Term View (1–3 months) 📈 Technical Setup ✅ Strong breakout from recent consolidation zone on above-average volume ✅ RSI surging to 70+, indicating positive momentum but nearing overbought zone ✅ Short-term support: ₹1,500–₹1,520 ✅ Resistance zone: ₹1,600–₹1,620 🔁 Expect short-term consolidation or mild retracement before next leg up ---------------------------------------------------------------------------------------- 📊 Long-Term View (6–12 months) 📌 Fundamental Strength ✔️ Q1 FY26 Revenue: ₹6,957 Cr (↑4% YoY) ✔️ EBITDA: ₹1,778 Cr (↑4% YoY) | EBITDA margin: 25.6% ✔️ PAT: ₹1,298 Cr (↑10% YoY) ✔️ Net cash position: ~₹10,800 Cr — robust balance sheet ✔️ Growth drivers:  🔹 Strong India + Emerging Market sales  🔹 U.S. pipeline with gAdvair, gSymbicort, biosimilars  🔹 Leading presence in respiratory, oncology & HIV 🎯 Analyst Targets: ₹1,800–₹1,875 in 6–12 months